Phase III trial evaluating sotorasib + panitumumab: MCC patients with rare tumor mutation experienced superior PFS compared to standard of care

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Guest Editorial

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Approximately 21 years ago, I had the privilege of working and helping to pass Proposition 71, which authorized $3 billion dollars in state bonds to fund stem cell research in California.

February 20, 2026

Vol.52 No.07

By Stephen J. Forman

Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

Autoimmune and inflammatory diseases arise when the immune system becomes misdirected, attacking the tissues it is meant to protect.

February 20, 2026

Vol.52 No.07

By Christine Brown and Enrique Montero

Clinical Roundup

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

KRAS is the most frequently mutated oncogene across all human cancers. Although different KRAS mutations have long been thought to exert the same cancer-driving effects, a new study led by UT Southwestern Medical Center researchers suggests that different KRAS mutation types can variously impact how cancer cells interact with immune cells, significantly affecting the malignant cells’ behavior.

February 20, 2026

Vol.52 No.07

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Prostate cancer remains a formidable challenge, particularly in its advanced stages, where bone metastases and treatment resistance dominate outcomes. At City of Hope, our focus is on leveraging immunotherapy to transform this landscape.

January 23, 2026

Vol.52 No.03

By Tanya Dorff

Phase III trial evaluating sotorasib + panitumumab: MCC patients with rare tumor mutation experienced superior PFS compared to standard of care

YOU MAY BE INTERESTED IN

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Rewriting immune regulation with the CD6/CTLA‑4 CAR‑Treg platform

Different KRAS mutations affect how tumors interact with the immune system, UTSW-led study finds

Opening doors to immunotherapy in prostate cancer: A roadmap from clinic to community

Renew today!

Subscriber content

Never miss an issue!

Login